AU2022376756A1 - Anti-cd47 antibodies and methods of use thereof - Google Patents

Anti-cd47 antibodies and methods of use thereof Download PDF

Info

Publication number
AU2022376756A1
AU2022376756A1 AU2022376756A AU2022376756A AU2022376756A1 AU 2022376756 A1 AU2022376756 A1 AU 2022376756A1 AU 2022376756 A AU2022376756 A AU 2022376756A AU 2022376756 A AU2022376756 A AU 2022376756A AU 2022376756 A1 AU2022376756 A1 AU 2022376756A1
Authority
AU
Australia
Prior art keywords
amino acid
seq
acid sequence
cdr
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022376756A
Other languages
English (en)
Inventor
Bin Cai
Zhengxi DAI
Fangyong Du
Yan Li
Guizhong Liu
Peter Peizhi Luo
Aaron NGUYEN
Jianfeng Shi
Jiangchun Xu
Songmao ZHENG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adagene Pte Ltd
Original Assignee
Adagene Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adagene Pte Ltd filed Critical Adagene Pte Ltd
Publication of AU2022376756A1 publication Critical patent/AU2022376756A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2022376756A 2021-10-27 2022-10-27 Anti-cd47 antibodies and methods of use thereof Pending AU2022376756A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPCT/CN2021/126597 2021-10-27
PCT/CN2021/126597 WO2023070353A1 (en) 2021-10-27 2021-10-27 Anti-cd47 antibodies and methods of use thereof
PCT/CN2022/127875 WO2023072177A1 (en) 2021-10-27 2022-10-27 Anti-cd47 antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
AU2022376756A1 true AU2022376756A1 (en) 2024-05-09

Family

ID=86160307

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022376756A Pending AU2022376756A1 (en) 2021-10-27 2022-10-27 Anti-cd47 antibodies and methods of use thereof

Country Status (9)

Country Link
US (1) US20240417463A1 (https=)
EP (1) EP4423138A4 (https=)
JP (1) JP2024542978A (https=)
KR (1) KR20240111823A (https=)
CN (1) CN118434769A (https=)
AU (1) AU2022376756A1 (https=)
CA (1) CA3235611A1 (https=)
TW (1) TW202334216A (https=)
WO (2) WO2023070353A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025010272A1 (en) 2023-07-03 2025-01-09 Neoimmunetech, Inc. Heterodimeric fc molecules and uses thereof
TW202517683A (zh) * 2023-07-20 2025-05-01 美商艾克塞里克斯公司 可活化之ror結合劑及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2477648B1 (en) * 2009-09-15 2022-07-20 The Board of Trustees of the Leland Stanford Junior University Synergistic anti-cd47 therapy for hematologic cancers
US9517276B2 (en) * 2013-06-04 2016-12-13 Cytomx Therapeutics, Inc. Compositions and methods for conjugating activatable antibodies
EP3668897B1 (en) * 2017-08-18 2024-06-05 Centessa Pharmaceuticals (UK) Limited Binding agents
KR20200091901A (ko) * 2017-12-01 2020-07-31 시애틀 지네틱스, 인크. 암을 치료하기 위한 cd47 항체 및 이의 용도
EP3802599B1 (en) * 2018-06-03 2023-12-20 LamKap Bio beta AG Bispecific antibodies against ceacam5 and cd47
MA53333A (fr) * 2018-07-31 2021-11-03 Amgen Inc Formulations pharmaceutiques d'anticorps masqués
US20220233709A1 (en) * 2019-06-05 2022-07-28 Seagen Inc. Masked Antibody Formulations
US20220306727A1 (en) * 2019-06-05 2022-09-29 Seagen Inc. Methods of Purifying Masked Antibodies
EP4034171A1 (en) * 2019-09-23 2022-08-03 Cytomx Therapeutics Inc. Anti-cd47 antibodies, activatable anti-cd47 antibodies, and methods of use thereof

Also Published As

Publication number Publication date
EP4423138A4 (en) 2026-03-04
TW202334216A (zh) 2023-09-01
KR20240111823A (ko) 2024-07-17
WO2023072177A1 (en) 2023-05-04
JP2024542978A (ja) 2024-11-19
CN118434769A (zh) 2024-08-02
WO2023070353A1 (en) 2023-05-04
US20240417463A1 (en) 2024-12-19
EP4423138A1 (en) 2024-09-04
CA3235611A1 (en) 2023-05-04

Similar Documents

Publication Publication Date Title
JP7678841B2 (ja) 抗ｃｔｌａ４抗体ならびにその作製及び使用方法
US20240150749A1 (en) Activatable antibodies and methods of making and using thereof
US10808030B2 (en) Anti-HCTLA-4 antibodies
US10494436B2 (en) Anti-PD-1 antibodies
WO2023072177A1 (en) Anti-cd47 antibodies and methods of use thereof
US20240209092A1 (en) Combination therapies for treating cancer
BR122023018935B1 (pt) Anticorpo, polinucleotídeo, vetor, célula hospedeira bacteriana, método de produção de um anticorpo, composição farmacêutica e uso do anticorpo